KDNY News and Press, Chinook Therapeutics Inc Com From 05/09/23

2023-05-09 18:05:33 ET Chinook Therapeutics press release ( NASDAQ: KDNY ): Q1 GAAP EPS of -$0.85. Revenue of $1.8M (-33.3% Y/Y). Cash, cash equivalents and marketable securities totaled $357.4 million at March 31, 2023, compared to $385.3 million at December 31, 2022....

SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and ...

Updated interim data to be presented from Cohort 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN Initial data to be presented from the phase 1 study of CHK-336 in healthy volunteers Additional presentations on the design of the phase 2 ASSIST ...

2023-04-27 09:17:35 ET Summary Part B portion of Phase 3 NefIgArd trial reveals positive outcomes for nefecon, leading to a reaffirmed buy recommendation for Calliditas. Nefecon demonstrates statistically significant stabilization of eGFR levels in IgAN patients, with consistent b...

2023-04-20 03:02:46 ET Summary On April 11th, KDNY announced a voluntary pause in the dosing of CHK-336 due to a serious adverse event in a single subject. We believe CHK-336's setback should not impact the IgAN readout and should be considered a clearing event. We maintain a ...

SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors....

2023-04-11 08:32:18 ET Chinook Therapeutics ( NASDAQ: KDNY ) lost ~8% pre-market Tuesday after the biotech announced that dosing in its Phase 1 study for oral therapy CHK-336 was on hold following a serious adverse event (SAE) in a single trial subject. An LDHA inhibitor t...

SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing in the phase 1 clinical trial of CHK-336 in health...

SEATTLE, March 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtu...

2023-03-27 08:19:05 ET Summary Omeros Corp's Q4 2022 earnings show a cash runway extending into 2025 and anticipation of Phase 3 trial readout of Narsoplimab in IgAN during 3Q23. The ARTEMIS Phase 3 trial in IgAN remains on track, and positive trial data could make Narsoplimab the...